New Leaf Venture Partners is a venture capital firm that invests primarily in healthcare technology. The company typically focuses on later stage biopharmaceutical products, early stage medical devices, and laboratory infrastructure technologies.  The New Leaf Ventures (NLV) team has been built over a decade, originating within Sprout Group, the venture capital affiliate of Credit Suisse First Boston. Sprout Group was formed in 1969 and has historically been one of the leading venture capital firms in the country. The team started to invest in healthcare technology in 1993 and since then, has become a leading venture investor in that sector. In 2005, the entire healthcare technology team of Sprout spun out into NLV.

New Leaf Venture Partners

Pritzker Group Venture Capital helps entrepreneurs build market-leading technology companies at every stage of their growth. Since its founding in 1996, the firm has worked side-by-side with entrepreneurs at more than 100 companies, building partnerships based on trust and integrity. Its proprietary capital structure allows for tremendous flexibility, and our experienced team of investment professionals and entrepreneurs offers companies a vast network of strategic relationships and guidance.  Successful exits in recent years include Fleetmatics (NYSE: FLTX), SinglePlatform (acquired by Constant Contact), Zinch (acquired by Chegg), Playdom (acquired by Disney), LeftHand Networks (acquired by Hewlett-Packard), and TicketsNow (acquired by Ticketmaster).

Pritzker Group Venture Capital

Tribeca Venture Partners is a multi-stage venture capital firm that invests in digital media, e-commerce, fintech, education, ad tech, and mobile apps sectors. The firm was founded in 2011 by Brian Hirsch and Chip Meakem and is based in New York, United States.

Tribeca Venture Partners

Biomatics Capital Partners is a Seattle-based healthcare and life sciences venture firm. Biomatics is a $200 million fund that focuses on early-stage investments, primarily in genomics and digital health. Co-founders and General Partners Dr. Boris Nikolic and Julie Sunderland have invested together in emerging technology, health care, and life science ventures since 2010, leveraging their deep technical knowledge and partnering expertise with an established network of leading academics, pharma executives and venture capital firms.

Biomatics Capital Partners

Baird Capital makes venture capital, growth equity, and private equity investments in strategically-targeted sectors around the world.  The company values its creators who identify exceptional opportunities and partners with senior industry executives to build world-class companies. Its in-depth sector knowledge, deep relationships with entrepreneurial management teams, and global network of 60 investment and operating professionals in the United States, the United Kingdom, and Asia help ensure that the company consistently drives value in its portfolio companies.  Baird Capital was founded on January 1, 1919 and is based in London, United Kingdom.

Baird Capital

We are a California-based private equity investor focused on providing growth stage capital to mid-sized enterprise software and tech-enabled companies. We focus on businesses with strong products in growing markets where we can facilitate a change in performance by scaling sales, strengthening leadership, and enhancing operations.

Palisades Growth

Silicon Valley Bank works with technology, life science, cleantech, venture capital, private equity, and premium wine businesses. SVB provides industry knowledge and connections, financing, treasury management, corporate investment, and international banking services to its clients worldwide through 27 U.S. offices and seven international operations.   Banking innovative companies and exclusive wineries, Silicon Valley Bank’s diverse financial services, knowledge, global network, and world-class service increase its clients’ probability of success. Forbes Magazine ranks SVB among America’s Best Banks, and Fortune Magazine named SVB one of the Best Companies to Work For in 2012.

Silicon Valley Bank

Accelmed is a venture capital firm that funds private and public medical device companies with significant market potential and proven clinical data. Concentrating on medical device companies that have already reached the revenue stage enables the firm to assist companies in benefiting from its managerial capabilities and financial resources. Together with the management teams of their portfolio companies, the Accelmed can steer the way from the clinical-stage to a profitable business with a clear commercial plan, thereby accelerating the path to a successful exit. In 2009, Mori Arkin and Uri Geiger, the co-founders of Accelmed, established the firm in Herzliya, Tel Aviv.

Accelmed

Asahi Kasei Corporation provides solutions based in chemistry and materials science to a range of markets, including fibers, chemicals, consumer products, housing, construction, electronics, and health care primarily in Japan. Segments Chemicals The Chemicals Segment offers organic and inorganic industrial chemicals, synthetic resin, synthetic rubber, high-compound fertilizer, coating materials, latex, pharmaceutical and food additives, explosives, photopolymers and platemaking systems, separation and ion-exchange membranes, systems, and equipment. The company produces, processes, and sells chemicals and derivative products, such as ammonia, nitric acid, caustic soda, acrylonitrile, styrene monomer, methyl methacrylate (MMA) monomer, PMMA resin, high-compound fertilizers, and adipic acid; polymer products, such as Suntec polyethylene (PE), Stylac-AS (styrene-acrylonitrile), Stylac-ABS (acrylonitrile-butadiene-styrene), synthetic rubber, Tenac polyacetal, Xyron modified polyphenylene ether (mPPE), and Leona nylon 66 polymer and filament); and specialty products, such as coating materials, latex, Ceolus microcrystalline cellulose, explosives, explosion-bonded metal clad, APR photosensitive resin and printing plate making systems, Microza UF and MF membranes and systems, Hipore microporous membrane, ion-exchange membranes and electrolysis systems, Saran Wrap cling film, Ziploc storage bags, and plastic films, sheets, and foams.

Asahi Kasei

Singtel Innov8, the venture capital arm of the Singtel Group, invests in and partners with innovative tech start-ups worldwide. It has a fund size of US$250 million and its own set of decision making, approval and funding processes. Beyond funding, Singtel Innov8 is a gateway for start-ups to tap on the resources and expertise of the Singtel Group, while enabling the Group to gain access to emerging technologies. Singtel Innov8 focuses its investments on technologies and solutions that can lead to quantum changes in network capabilities, next generation devices, digital services and enablers to enhance customer experience. Headquartered in Singapore, Singtel Innov8 also has offices in San Francisco and Tel Aviv.

Singtel Innov8

SpringRock Ventures is a venture capital firm that helps entrepreneurs building compelling companies in an evolving sector. The venture capital firm focuses on digital health, devices, services, oral health, SAAS, consumerization/eCommerce of healthcare, IT, wellness, HIPAA and other innovative companies improving general health. They invest in early to late-stage, high growth-potential companies with some demonstrated customer acceptance.  SpringRock Ventures was founded in 2015 and is based in Seattle, Washington, USA.

SpringRock Ventures

AiCure

AiCure is an advanced data analytics company that uses artificial intelligence to understand how patients respond to treatments. It enables intelligent decision-making and improving health outcomes. It has developed patented facial recognition and motion-sensing technology to confirm medication ingestion in real-time. AiCure's platform has the potential to revolutionize the cost-effectiveness of healthcare delivery systems by enhancing treatment and reducing risks. Their software captures and understands video, audio, and behavioral data to establish the link between patients, disease, and treatment. It was founded in 2010 and is headquartered in New York.

<div>AiCure is an advanced data analytics company that uses artificial intelligence to understand how patients respond to treatments. It enables intelligent decision-making and the improvement of health outcomes. It has developed patented facial recognition and motion-sensing technology to confirm medication ingestion in real-time. Their software captures and understands video, audio, and behavioral data to establish links between patients, disease, and treatments. In 2019, the company increased revenue by more than 65% YoY, driven by new customer acquisitions. The company has filed for more than 110 patents and has a global client base in over 30 countries.</div>

Facial recognition delivers incredible convenience to consumers, as well as serious risks.

Facial Recognition

AiCure is a data analytics company that primarily offers a platform for the collection and management of patient data. The platform supports a range of patient tasks during a clinical trial, including 1) data collection from patients for dosage and patient reported outcomes, 2) reminders and connectivity for remote visits, and 3) payments and reimbursements for patients completing dosing or assessments. Additionally, the platform provides real-time data insights and analytics to sponsors. In terms of compliance, the platform meets industry standards including HIPAA and GDPR.

Incorporating technology to improve efficiency and success rate of clinical trials

Clinical Trial Technology

AiCure Bringing New Patient Engagement Platform H.Code to DPHARM 2024

<div>
 
 AiCure is an advanced data analytics company that uses artificial intelligence to understand how patients respond to treatments. It enables intelligent decision-making and the improvement of health outcomes. It has developed patented facial recognition and motion-sensing technology to confirm medication ingestion in real-time. Their software captures and understands video, audio, and behavioral data to establish links between patients, disease, and treatments. In 2019, the company increased revenue by more than 65% YoY, driven by new customer acquisitions. The company has filed for more than 110 patents and has a global client base in over 30 countries.
 
 
 In April 2022, the company announced 
 <a href="https://sp-edge.com/updates/9588?industryIds=16">
 global expansion
 </a>
 through a partnership with Italian technology and services company for advanced healthcare Qwince, and opening of its first international office in Nanjing, China, to attract new talent and perspective.
 
 
 
</div>

<div>
 
 Founded in Spain, FacePhi offers a wide range of facial recognition identity authentication solutions for transaction approval and digital onboarding. FacePhi&rsquo;s Selphi software allows the user to conduct ID authentication by using a selfie. The selfie is encrypted and sent to the bank&rsquo;s database to be used in payee authentication. The encryptions ensure the user's privacy as the full image is not sent to the bank. The company&rsquo;s revenue increased by around 143% during the first half of 2020 (compared to the same period in 2019) on account of agreements with 10 new clients, compared to 13 new customers during 2019 (full year), indicating the growth potential of the company.
 
 
 In May 2021, FacePhi partnered with Revelock, a Spanish fraud detection company, to provide comprehensive identity verification and fraud prevention solutions for financial institutions. In February 2022, the company partnered with software company Oracle Cloud Marketplace, for the latter to work as a distributor for FacePhi's digital onboarding and facial recognition solutions. In November 2021, the company also partnered with airport operator Aena to offer identity verification for passengers and employees at a price of USD 1.7 million for four years. With the aim of expanding presence in the LATAM region, FacePhi established a regional office in Uruguay in March 2022, followed by an agreement with 
 <a href="https://sp-edge.com/updates?industryIds=16">
 Hites,
 </a>
 a Chilean department store, to use remote selfie onboarding technology to let Hites&rsquo; customers apply for credit cards online. In May 2022, FacePhi opened another
 <a href="https://sp-edge.com/updates/10796?industryIds=16">
 office in the UK
 </a>
 to serve Europe, the Middle East, and Africa (EMEA) regions.
 
 
 Funding and financials
 
 
 During the fiscal year 2022, FacePhi recorded net revenues of EUR 2.2 million ( ~USD 2.3 million), growing 69% YoY, and an adjusted EBITDA of EUR 4.3 million ( ~USD 4.6 million), unchanged from the previous year.
 
 
 
</div>

FacePhi

Headquartered in the Netherlands, Sightcorp is an AI spin-off from the University of Amsterdam that develops patented proprietary AI Software solutions for mobile apps, including face detection (detect multiple faces in an image), emotion analysis, crowd demographics, and attention analytics. The main target markets of the company include retail, advertising, hospitality, and digital signage.In January 2022, Sightcorp was <a href="https://sp-edge.com/updates/7828?industryIds=16">acquired by Raydiant </a>, a provider of an in-location experience management platform, to jointly develop solutions for personalized on-screen, in-location experiences targeting retailers, restaurants, etc. Sightcorp expects to open offices in Lithuania and London in 2022 and to grow its European team from 20 to 100. Raydiant is also hiring across the US and internationally to accompany Sightcorp’s new offices.

Sightcorp

<div>
 
 Okaya offers a mobile app that aims to understand users&rsquo; wellbeing by using a combination of facial recognition technology, biometrics analysis (such as heart rate, weight, etc.), and machine learning. Okaya&rsquo;s facial recognition algorithm, developed in-house, analyses facial features obtained from a 15-second video recording where up to 30 frames are captured in a second. This data is evaluated along with other biometrics to determine a person&rsquo;s level of fatigue. The product claims to help create strong work teams and a robust work environment allowing the identification of areas where improvement is required.
 
</div>

Okaya

<div>
 
 Facetec offers a 3D face authentication software called ZoOm capable of high-performance liveness detection (verification of whether facial features captured are from a living subject). The software can work on smart mobile devices and webcams. The company also has patented technology to generate a 3D face map using a video selfie recorded even with a 2D camera. In September 2019, Facetec improved its product by embedding an age-estimation tool. Even though selfie-based authentication has become commonplace, many of them uses 2D facial mapping which makes it are vulnerable to spoofing attacks (trying to obtain access illegitimately by reproducing a person's face using images, masks, mannequins etc.) due to use of 2D mapping of facial features. FaceTec's technology is superior to others as it allows to create a 3D map of the face even with a normal 2D camera. While most other 3D face mapping requires designated hardware components, FaceTec's technology eliminates this requirement. Hence, it does not require app developers to rely on device manufacturers to incorporate additional hardware to use ZoOm. The company claims its product is one of the few companies to be certified in level 1 and 2 in iBeta Presentation Attack Detection (PAD) testing directed by an ISO standard. The software can detect digital and physical 'spoof artifacts' such as high-resolution photos and videos, masks and mannequins. FaceTec has over 100 customers across various verticals with an installed base of over 10 billion smart devices. ZoOm targets a wide range of markets ranging from banking, e-commerce, healthcare, insurance, e-voting, attendance, and government. Majority of FaceTec's customers are currently government and financial institutions.
 
</div>

FaceTec, Inc.

<div>
 
 FaceFirst offers facial recognition solutions mainly for access control as well as for identity authentication and real-time security. It focuses on retailers, airports, casinos, banks, as well as music and gaming events. The company also offers a mobile app (for iOS and Android) for facial recognition on the go. FaceFirst&rsquo;s facial recognition tool is mainly aimed at the retail segment, which accounts for around 50% of its business. FaceFirst&rsquo;s patented retail security platform can identify any known shoplifters or forbidden employees attempting to enter the store. Its products can be integrated with existing retail systems. 
 
 
 The company also introduced Mask-ID in November 2018, which instantly blurs identified faces without compromising accuracy. Additionally, the retail security platform allows its users to access the company&rsquo;s database of retail criminals, enabling them to include any individuals banned by the company itself. FaceFirst is one of the companies to work with lawmakers to help regulate the industry.
 
</div>

FaceFirst

Companies that are developing facial recognition technology to suggest tags for photos uploaded on the platform, typically social media.

Companies that provide facial recognition technology for contactless and fast-payment gateways.

Companies providing tools to identify VIP customers and repeat customers by using facial recognition.

Companies that provide technology to monitor physical access to offices, retail stores, and residences as well as access to electronic devices, such as mobile phones and laptops, using facial recognition.

Companies providing facial recognition technology to identify people from live and recorded videos.

Companies that provide facial recognition technology to police and government agencies to identify criminals, protestors, unauthorized overstayers in the country, and departing passengers.

Facial recognition is a type of biometrics used to verify individuals

Used in smart city applications for access control

Facial recognition technology is built on ML models for training data

AiCure is a data analytics company that primarily offers a platform for the collection and management of patient data. The platform supports a range of patient tasks during a clinical trial, including 1) data collection from patients for dosage and patient reported outcomes, 2) reminders and connectivity for remote visits, and 3) payments and reimbursements for patients completing dosing or assessments. Additionally, the platform provides real-time data insights and analytics to sponsors. In terms of compliance, the platform meets industry standards including HIPAA and GDPR.Key customers and partnershipsAs of June 2024, AiCure’s platform was accessible across 46+ countries, was used at 2,200+ sites, and collected data for over 1.5 million patients. As of April 2022, the company partnered Italian tech company Qwince to drive expansion into the European market. Additionally, AiCure partnered with Syneos Healthcare in November 2019 to deploy AiCure solutions across Syneos clinical research sites.By 2021, AiCure recorded over a million patient interactions through its AiCure Patient Connect system, which incorporates vision and AI technology.Funding and financialsThe company raised USD 24.5 million in Series C funding in 2019 led by Palisades Growth Capital. The proceeds were to be used to accelerate product development activities relating to AI-driven insights.

Headquartered in Amsterdam, Castor is a cloud-based e-clinical data platform that can be used for a range of tasks and processes during a clinical trial. It offers four solutions: 1) electronic data capture (EDC) to capture and process data from multiple sources including researchers, 2) electronic patient-reported outcomes (ePRO) to collect and manage patient-reported data on a centralized platform, 3) e-consent - to enable patients to be recruited, screened, and enrolled remotely, and 4) a decentralized clinical trials (DCT) platform to assist operators with managing DCT technologies and devices through a central platform. The company’s solutions are targeted at industries like biotech and pharma, diagnostics, and clinical research organizations. Its solutions are built in line with industry-standard compliance and data protection standards including HIPAA, GDPR, and ISO 27001.Castor aimed to collect enough clinical trial research data to enable the reuse of data for AI-driven clinical trials, which would lower the costs of operating clinical trials and reduce the time taken to bring new drugs to market.Key customers and partnershipsAs of June 2024, the company had supported 14,000+ studies and 6 million patients through clinical trials across 90+ countries, since launching in 2007. In terms of therapeutic areas, Castor had supported a range of different areas, including oncology, cardiovascular diseases, and diabetes. The company had been engaged by 500+ organizations, including the World Health Organization, Click Therapeutics, and Stryker. It was the first to incorporate machine learning into its system for the identification of Covid-19 patients. The company offered free access to its system for Covid-19 research projects, with over 200 projects using the platform as of June 2022. In February 2024, the company partnered with Microsoft to use Microsoft Azure to bring modern AI to clinical trials. The feature was released to help Castor users develop their studies faster by simplifying complex tasks in the study build process. The company additionally noted that it was planning to release its first in a line of Practical AI features to all its users in public Beta. Funding and financialsThe company raised USD 45 million in Series B funding in July 2021, led by Eight Roads Ventures and F-Prime Capital. The funds were earmarked for product development, interoperability with partner systems, and market research on decentralized trials. The company had a headcount of 150 at the time of the Series B and was planning to expand to 200 by the end of 2021.

Castor

Florence Healthcare offers a platform for clinical trial management. It has four key components: 1) SiteLink to start-up and monitor remote clinical sites, 2) eBinders to digitize and store research binders, 3) eConsent to simplify and digitize the consent process, and 4) Electronic Trial Master File to digitize the storage and transfer of files between sites and research sponsors. The platform is compliant with standard industry requirements including HIPAA, 21 C.F.R Part 11, ICF/GCP, and GDPR.Key customers and partnershipsAs of June 2024, Florence supported over 18,000 research sites, across 55+ countries, with key customers including Pfizer. The usage of the company’s software tripled in 2020, driven by an industry shift toward digitalization as a result of the Covid-19 pandemic. In February 2022, the company was ranked as the best clinical trial platform out of a group of 190 for ease of setup, ease of use, and customer support.Florence partnered with Greenphire, a company focusing on patient convenience and financial management for clinical trials, in Janauary 2024. Through the partnership, Florence's platform will be integrated with Greenphire's to improve payment systems within clinical trials. Benefits of the partnership included reduced manual work for sites, faster payments, and better visibility of site activity for sponsors and Contract Research Organizations (CROs). Funding and financialsThe company raised USD 80 million in Series C funding in May 2021 led by Insight Partners. The proceeds were to be used to scale up its sales and marketing teams and improve the value proposition of the platform by reducing the time required by customers to implement and manage clinical trials.

Florence Healthcare

Huma is a UK- and US-based clinical trial tech startup that provides a digital platform to manage clinical trials, including decentralized clinical trials. The platform can be used throughout the clinical trial process, including patient recruitment, screening, electronic consent, clinical outcome assessments, patient-reported outcomes, and telemedicine. The platform is built up to industry standards in data privacy and security, including ISO 27001, 21 C.F.R. Part 11, and TxP.In June 2023, the company <a href="https://sp-edge.com/updates/19352">received FDA 510(k) Class II FDA clearance </a>for its configurable disease-agnostic platform, including its cardiovascular risk score algorithm. The company received this FDA clearance in partnership with Health Canada and it allows Huma's platform to be used to monitor patients of all ages with any condition, including pediatrics and pregnancy. The Class II clearance also enables the platform to host algorithms that provide automated AI-driven data analytics for diagnosis, screening, clinical decision-making, predictions on health outcomes, and recommendations on dosage.In July 2024, the company was <a href="https://sp-edge.com/updates/31552">estimated to be valued at nearly USD 1 billion</a> when it secured a Series D investment of USD 80 million. Key customers and partnershipsSome of the key partners working with Huma include AstraZeneca, Johnson &amp; Johnson, Bayer, Stanford University, and the University of Cambridge. As of July 2024, the platform supported 3,000+ hospitals and clinics, screened over 35 million individuals, and had 1.8 million active users across 70 countries. Huma was awarded the 2021 Prix Galien Award, which is widely considered the “Nobel Prize” for pharmaceuticals and life sciences.The company announced a partnership with Xyla Elective Care in June 2022, to provide support to the UK’s National Health Service in delivering and managing virtual wards.

Huma

Based in California and founded in 2015, Medable is a digital clinical trial management platform with a range of modules for different processes. These modules include a decentralized clinical trial platform to support decentralized trials using remote tools for data gathering, monitoring, televisits, and consent; digital patient screening to screen patients remotely and at scale; e-consent to enable patients to digitally consent for clinical trials; electronic clinical outcome assessments; and patient-reported outcomes to document data in real time and provide easy access for researchers. It also includes remote patient monitoring to make it easy for patients to record and share data with clinical research teams.Medable operates on a SaaS business model, with customers having the option of selecting and deploying only the modules required as part of their uniquely customized solution.In <a href="https://sp-edge.com/updates/32647">August 2024</a>, Medable launched 'Medable Studio', an all-in-one application for configuring, translating, validating, and launching electronic clinical outcome assessment (eCOA) Plus solutions (which include eCOA, e-consent, televisits, and sensors) into clinical trials. The no-code suite aimed to simplify the complex eCOA launch process, offering biopharmaceutical companies greater control and transparency. Medable Studio includesda point-and-click builder for creating assessments and instruments, a visual schedule of assessments builder, a translation workbench, and a content library. The platform enabled users to rapidly build and launch complex clinical trials, with the ability to create protocol-fit study designs in hours instead of months.In <a href="https://sp-edge.com/updates/35913">November 2024</a>, Medable launched Medable AI, a suite of GenAI capabilities integrated into its Studio platform. The suite aimed to streamline digital and decentralized clinical trials for sponsors and research organizations. The AI suite features automated eCOA creation that converts existing outcome assessments into a digital format, a ChatGPT-like interface for editing assessments, and scalable assessment-generation capabilities.&nbsp;As of <a href="https://hitconsultant.net/2024/10/30/medable-partners-with-google-cloud-to-accelerate-clinical-trials/">October 2024</a>, the company offered its platforms across 60 countries and was used across 300 decentralized and hybrid clinical trials. The company’s platform is compliant with industry standards, including HIPAA, FDA’s 21 CFR Part 11, and GDPR.Key customers and partnershipsAs of <a href="https://www.businesswire.com/news/home/20240607926468/en/Medable-Wins-2024-Prix-Galien-UK-Award-for-Best-Digital-Health-Solution">June 2024</a>, Medable claimed to work with 14 out of the top 20 pharmaceutical companies, in addition to working with a range of partners, including Cognizant, Accenture, Oracle, and PwC.In <a href="https://sp-edge.com/updates/35456">October 2024</a>, the company partnered with Google Cloud to offer its decentralized clinical trial platform on Google Cloud's marketplace. The collaboration combined Medable's clinical trial technology with Google Cloud's infrastructure and AI capabilities to streamline trial processes.In <a href="https://sp-edge.com/updates/29843">May 2024</a>, Medable partnered with Masimo, a medical technology provider, to incorporate new wearable devices in clinical research. Medable announced it would include the MightySat Rx pulse oximeter by Masimo in its platform for various major clinical trials, particularly in lung and breast cancer research.In <a href="https://sp-edge.com/updates/22394">October 2023</a>, the company partnered with Pluto Health, a healthcare coordination company, to enhance the clinical trial experience for participants and improve data collection during trials. Through the partnership, the companies aimed to connect patients to the right medical resources including access to clinical trials and home delivery of medication.&nbsp;In <a href="https://www.fiercebiotech.com/biotech/gsk-taps-medable-decentralized-clinical-trials-patient-diversity">September 2022</a>, the company announced a four year agreement with GlaxoSmithKline to use Medable’s platform for clinical trials across multiple products. Financial terms of the agreement were not disclosed.

Medable

Headquartered in New York, Obvio Health provides a full service for clients, supporting them throughout the clinical trial process from the design and recruitment stages to outcome measurement and reporting. In addition to its technological platform, the company provides professional services to execute clinical trials using its in-house clinical operations team. The platform caters to 17 therapeutic areas, including cardiology, oncology, respiratory, men's and women's health, dermatology, gi, hepatology, mental health, oral health, and infectious disease (Covid-19). The platform is compliant with industry standards including 21 CFR Part 11, ICH-GDP, GDPR, and ISO 27001.According to the company, its platform was designed from the ground up to cater to digital trials run by virtual clinical teams, which resulted in faster patient recruitment (three months for Obvio compared to 12 months for physical site trials). In January 2022, the company launched an augmented electronic patient-reported outcome (augmented ePRO) module, which incorporates AI and manual scoring by experts/clinicians. The company claims this improves the accuracy and quality of data collected.In April 2024, the ObvioHealth launched ObvioGo 2.0, an enhanced platform and mobile application designed to meet the unique needs of trial sites and sponsors. The upgraded platform allows the combination of hybrid and virtual trial designs within one study. It includes features such as the ability to create site-specific workflows, integration with other clinical systems, and a streamlined translation process. Additional features include a built-in virtual assistance team, COACH, for trial tasks support and a patient identifier tool for patient registration and data correlation.As of June 2024, the platform catered to 17 therapeutic areas, including cardiology, oncology, respiratory, men's and women's health, dermatology, GI, hepatology, mental health, oral health, and infectious disease (Covid-19). The platform is compliant with industry standards including 21 CFR Part 11, ICH-GDP, GDPR, and ISO 27001. Key customers and partnershipsAs of June 2024, Obvio Health’s client base included companies like GlaxoSmithKline, Pfizer, Bayer, Danone, and General Mills. As of June 2024, the company’s operations were spread over 28 countries and had supported obtaining consent from 40,000+ patients across 40 clinical trials since its launch.In March 2022, Obvio partnered with Renovia to conduct the first fully virtual trial in urogynaecology, based on Renovia’s Leva device. The device helped patients with performing kegel exercises more effectively, in addition to monitoring compliance over the trial period.In November 2023, Obvio then partnered with Chemist Warehouse, the largest retail pharmacy chain in Australia, to improve the reach and efficiency of clinical trials. Through the partnership, Chemist Warehouse agreed to promote ObvioHealth-managed trials to its customers in Australia, using both offline and online channels. Additionally, ObvioHealth agreed to utilize Chemist Warehouse's Telehealth services for studies that require clinician assessments. The collaboration aimed to increase the awareness and convenience of clinical trials, addressing two major hurdles in participant recruitment. The long-term goal of the partnership was to expedite the introduction of innovative therapies to the market more efficiently and economically. Funding and financialsThe company raised USD 31 million of Series B funding in June 2021 led by Dedalus Group and Novotech Health. The investment was primarily strategic, with Obvio benefiting from its Dedalus partnership in terms of European clinical trial compliance, while it became Novotech Health’s preferred virtual clinical trial provider.

Obvio Health

Companies offering data and workflow management platforms and solutions to assist with the operational management of a clinical trial, including site management, monitoring processes in terms of risk and documentation, and payment automation.

Companies using remote patient monitoring tools and other connectivity solutions to enable remote collection of patient data and monitoring and run trials virtually, without requiring the patient to be physically present in the clinical trial site.

Companies that offer workflow management platforms that are used to manage logistics tasks and processes for clinical trials, primarily the randomization of assigning patients in a clinical trial and automation of logistics workflows based on clinical trial data.

This is the use of software, incorporating AI and Machine Learning technology to improve the matching process of patients with suitable clinical trials.

Companies that offer software solutions for identifying and evaluating potential trial sites, along with documentation and workflow management systems to complete the processes before launching, including electronic patient consent and other required regulatory tasks.

Includes companies that provide digital data management platforms to collect and store patient reported outcome data. These platforms are also incorporating data analytics to help understand the results and identify trends and patterns. Additionally, the platforms are enabling connectivity with remote monitoring devices, including Medical Internet of Things.

Companies that provide software tools that help with the design of clinical trials, including identifying protocol violations, collecting participant input on potential design ideas for the trial, and crowdsourcing of protocol ideas for clinical trials.

Companies that use GenAI as a core part of their product offering for Clinical Trial Tech

Startups in this hub use IoT to support report patient monitoring and data gathering

AI/ML algorithms can be used to automate the analysis of patient data

Offers digital platforms that accelerate clinical trials and evaluations

Most CTT platforms are offered on a B2B basis to companies carrying out clinical trials

Startups in this hub seek to improve clinical trial diversity by including underrepresented communities

Clinical Trial Technology providers incorporate GenAI to enhance their platform’s capabilities and utility

<div>
 
 AI health company AiCure has secured USD 12 million through loan refinancing and received an additional USD 4 million from ongoing investors.
 These funds are aimed towards operational expansion, product enhancement, and investment in research and development.
 
</div>

AiCure

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless